GB201616365D0 - Non-genetic modification of enveloped viruses - Google Patents

Non-genetic modification of enveloped viruses

Info

Publication number
GB201616365D0
GB201616365D0 GBGB1616365.1A GB201616365A GB201616365D0 GB 201616365 D0 GB201616365 D0 GB 201616365D0 GB 201616365 A GB201616365 A GB 201616365A GB 201616365 D0 GB201616365 D0 GB 201616365D0
Authority
GB
United Kingdom
Prior art keywords
genetic modification
enveloped viruses
enveloped
viruses
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1616365.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Helsinki
Original Assignee
University of Helsinki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Helsinki filed Critical University of Helsinki
Priority to GBGB1616365.1A priority Critical patent/GB201616365D0/en
Publication of GB201616365D0 publication Critical patent/GB201616365D0/en
Priority to CA3035104A priority patent/CA3035104A1/en
Priority to AU2017337753A priority patent/AU2017337753B2/en
Priority to CN201780056649.7A priority patent/CN109890957A/zh
Priority to EP17765150.2A priority patent/EP3519565A1/en
Priority to PCT/EP2017/072366 priority patent/WO2018059896A1/en
Priority to US16/337,220 priority patent/US10982194B2/en
Priority to BR112019005825-7A priority patent/BR112019005825A2/pt
Priority to NZ751251A priority patent/NZ751251B2/en
Priority to RU2019110407A priority patent/RU2760521C2/ru
Priority to JP2019515292A priority patent/JP7258746B2/ja
Priority to KR1020197012062A priority patent/KR102599401B1/ko
Priority to ZA2019/02388A priority patent/ZA201902388B/en
Priority to JP2022197406A priority patent/JP2023029997A/ja
Priority to AU2023237201A priority patent/AU2023237201B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
GBGB1616365.1A 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses Ceased GB201616365D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
KR1020197012062A KR102599401B1 (ko) 2016-09-27 2017-09-06 엔벨로프 바이러스의 비-유전적 변형
US16/337,220 US10982194B2 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
NZ751251A NZ751251B2 (en) 2017-09-06 Non-genetic modification of enveloped viruses
CN201780056649.7A CN109890957A (zh) 2016-09-27 2017-09-06 非遗传修饰的包膜病毒
EP17765150.2A EP3519565A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
CA3035104A CA3035104A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
BR112019005825-7A BR112019005825A2 (pt) 2016-09-27 2017-09-06 vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer
AU2017337753A AU2017337753B2 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses
RU2019110407A RU2760521C2 (ru) 2016-09-27 2017-09-06 Негенетическая модификация оболочечных вирусов
JP2019515292A JP7258746B2 (ja) 2016-09-27 2017-09-06 エンベロープウイルスの非遺伝的改変
ZA2019/02388A ZA201902388B (en) 2016-09-27 2019-04-15 Non-genetic modification of enveloped viruses
JP2022197406A JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変
AU2023237201A AU2023237201B2 (en) 2016-09-27 2023-09-29 Non-genetic modification of enveloped viruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses

Publications (1)

Publication Number Publication Date
GB201616365D0 true GB201616365D0 (en) 2016-11-09

Family

ID=57539741

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1616365.1A Ceased GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses

Country Status (12)

Country Link
US (1) US10982194B2 (cg-RX-API-DMAC7.html)
EP (1) EP3519565A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258746B2 (cg-RX-API-DMAC7.html)
KR (1) KR102599401B1 (cg-RX-API-DMAC7.html)
CN (1) CN109890957A (cg-RX-API-DMAC7.html)
AU (2) AU2017337753B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035104A1 (cg-RX-API-DMAC7.html)
GB (1) GB201616365D0 (cg-RX-API-DMAC7.html)
RU (1) RU2760521C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018059896A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902388B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
CA3152796A1 (en) * 2019-08-27 2021-03-04 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108047A1 (en) 1998-08-27 2001-06-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
CA2390081C (en) * 1999-10-29 2011-07-05 University Of Southern California Modified viral surface proteins which bind to cells of tumor vasculature
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US7432045B2 (en) * 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
NO2700405T3 (cg-RX-API-DMAC7.html) * 2008-05-29 2018-09-01
US10603351B2 (en) * 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
SG176554A1 (en) * 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2847305T3 (es) * 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
JP6705755B2 (ja) 2014-05-19 2020-06-03 バロ セラピューティクス オイValo Therapeutics Oy 癌ワクチン開発のための改変アデノウイルス

Also Published As

Publication number Publication date
BR112019005825A2 (pt) 2019-06-11
RU2019110407A3 (cg-RX-API-DMAC7.html) 2021-05-13
AU2023237201A1 (en) 2023-12-14
AU2023237201B2 (en) 2025-06-05
RU2760521C2 (ru) 2021-11-26
JP2019532631A (ja) 2019-11-14
KR102599401B1 (ko) 2023-11-06
CA3035104A1 (en) 2018-04-05
ZA201902388B (en) 2020-10-28
JP2023029997A (ja) 2023-03-07
US20200010811A1 (en) 2020-01-09
WO2018059896A1 (en) 2018-04-05
JP7258746B2 (ja) 2023-04-17
EP3519565A1 (en) 2019-08-07
US10982194B2 (en) 2021-04-20
KR20190053260A (ko) 2019-05-17
AU2017337753A1 (en) 2019-03-21
RU2019110407A (ru) 2020-10-29
AU2017337753B2 (en) 2023-09-28
CN109890957A (zh) 2019-06-14
NZ751251A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
GB2558826B (en) Mitigation of anti-sandbox malware techniques
PL3250239T3 (pl) Kapsyd
SG11201706729SA (en) Derivatives of sobetirome
IL273932A (en) Methods of treatment and prevention of viral infection
ZA201706257B (en) Treatment of wood
IL257026A (en) Solid state forms of eluxadoline
GB201617085D0 (en) Compare and delay instructions
GB2540405B (en) Execution of micro-operations
ZA201902388B (en) Non-genetic modification of enveloped viruses
ZA201706282B (en) Solid forms of menaquinols
GB201517432D0 (en) Splint
GB2543602B (en) Mitigation of anti-sandbox malware techniques
IL258137A (en) HIV treatment measures
SG10202104023QA (en) Validation of continuous viral clearance
GB2545220B (en) Underpants
GB201604145D0 (en) Disinfection of foodstuffs
GB2539974B (en) Carrying aid with noose
HK40016150A (en) Non-genetic modification of enveloped viruses
GB201519786D0 (en) Disinfection of foodstuffs
GB201512139D0 (en) Methods of treatment
GB201510870D0 (en) Treatment of infarction
GB201504126D0 (en) Trusted networks
PH32015000758S1 (en) Set of earbuds
GB201600380D0 (en) Modified virus

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)